Trial finds benefit to genotype-guided antiplatelet therapy

11/12/2013 | Medscape (free registration)

Patients with clopidogrel loss-of-function gene patterns who received a stent for acute myocardial infarction saw a sharp decline in ischemic events in one year as a result of genotype-guided antiplatelet therapy, according to the GIANT trial. The trial included 316 patients with the LOF genotype, 86% of whom had their prescribed antiplatelet therapy adjusted in response to assay results. The one-year composite risk of death, heart attack or stent thrombosis was similar to that of patients who didn't have the high-risk genotype, according to the study, while the end point composite was five times higher for those whose therapy was not changed based on the findings. SCAI fellow Dr. Cindy Grines called the findings "amazing."

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide